A detailed history of China Universal Asset Management Co., Ltd. transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 20,607 shares of TNGX stock, worth $80,779. This represents 0.02% of its overall portfolio holdings.

Number of Shares
20,607
Previous 12,552 64.17%
Holding current value
$80,779
Previous $107,000 47.66%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$7.36 - $11.93 $59,284 - $96,096
8,055 Added 64.17%
20,607 $158,000
Q2 2024

Jul 19, 2024

SELL
$6.66 - $10.15 $46,733 - $71,222
-7,017 Reduced 35.86%
12,552 $107,000
Q1 2024

Apr 29, 2024

BUY
$7.51 - $12.88 $58,397 - $100,154
7,776 Added 65.94%
19,569 $155,000
Q4 2023

May 21, 2024

SELL
$6.52 - $12.01 $50,699 - $93,389
-7,776 Reduced 39.74%
11,793 $116,000
Q4 2023

Jan 23, 2024

BUY
$6.52 - $12.01 $62,135 - $114,455
9,530 Added 421.12%
11,793 $117,000
Q3 2023

May 21, 2024

BUY
$2.93 - $11.26 $3,237 - $12,442
1,105 Added 95.42%
2,263 $25,000
Q3 2023

Oct 30, 2023

BUY
$2.93 - $11.26 $3,237 - $12,442
1,105 Added 95.42%
2,263 $25,000
Q2 2023

May 21, 2024

SELL
$2.67 - $4.7 $98 - $173
-37 Reduced 3.1%
1,158 $3,000
Q2 2023

Jul 27, 2023

SELL
$2.67 - $4.7 $98 - $173
-37 Reduced 3.1%
1,158 $4,000
Q1 2023

May 21, 2024

BUY
$3.76 - $8.06 $1,124 - $2,409
299 Added 33.37%
1,195 $4,000
Q1 2023

Apr 27, 2023

BUY
$3.76 - $8.06 $1,124 - $2,409
299 Added 33.37%
1,195 $5,000
Q4 2022

May 21, 2024

SELL
$3.41 - $8.29 $63,674 - $154,799
-18,673 Reduced 95.42%
896 $6,000
Q4 2022

Jan 31, 2023

BUY
$3.41 - $8.29 $3,055 - $7,427
896 New
896 $6,000

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $345M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.